DE60042704D1 - Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig - Google Patents

Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig

Info

Publication number
DE60042704D1
DE60042704D1 DE60042704T DE60042704T DE60042704D1 DE 60042704 D1 DE60042704 D1 DE 60042704D1 DE 60042704 T DE60042704 T DE 60042704T DE 60042704 T DE60042704 T DE 60042704T DE 60042704 D1 DE60042704 D1 DE 60042704D1
Authority
DE
Germany
Prior art keywords
hsp
binding domain
atp binding
individual
independent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042704T
Other languages
German (de)
English (en)
Inventor
Qian Huang
Joan F L Richmond
Bryan K Cho
Deborah Palliser
Jianzhu Chen
Herman N Eisen
Richard A Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Original Assignee
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE60042704D1 publication Critical patent/DE60042704D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60042704T 2000-01-14 2000-12-01 Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig Expired - Lifetime DE60042704D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17614300P 2000-01-14 2000-01-14
PCT/US2000/032831 WO2001051081A1 (en) 2000-01-14 2000-12-01 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent

Publications (1)

Publication Number Publication Date
DE60042704D1 true DE60042704D1 (de) 2009-09-17

Family

ID=22643163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042704T Expired - Lifetime DE60042704D1 (de) 2000-01-14 2000-12-01 Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig

Country Status (8)

Country Link
US (3) US6875435B2 (https=)
EP (1) EP1253939B1 (https=)
JP (1) JP2003519668A (https=)
AT (1) ATE438408T1 (https=)
AU (2) AU1814101A (https=)
CA (1) CA2396384A1 (https=)
DE (1) DE60042704D1 (https=)
WO (1) WO2001051081A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
JP2005512517A (ja) * 2001-09-27 2005-05-12 イ・デ・エム・イミュノ−デジネ・モレキュル 誘導性Ｈｓｐ７０由来のポリペプチドとこのポリペプチドを含有する医薬組成物
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
RU2333767C2 (ru) * 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
US8742068B2 (en) * 2007-07-06 2014-06-03 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017156461A2 (en) * 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
US4557931A (en) 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
IE56720B1 (en) 1983-02-07 1991-11-20 Battelle Memorial Institute Methods and compositions for expression of competent eukaryotic gene products
US4797359A (en) 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
AU6713287A (en) 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
EP0345299A1 (en) 1987-02-02 1989-12-13 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
WO1990015873A1 (en) 1989-06-19 1990-12-27 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
ATE127345T1 (de) 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
EP0467972A4 (en) 1989-04-06 1992-09-02 Washington State University Research Foundation Rickettsial antigens for vaccination and diagnosis
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
ATE154759T1 (de) 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (en) 1991-06-14 1993-01-07 Institut Pasteur Recombinant immunogenic actinomycetale
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2171454T3 (es) 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
ES2245778T3 (es) 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
IL123218A0 (en) 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Heat shock protein-based vaccines and immunotherapies
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
US6455493B1 (en) * 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
EP1047451A1 (en) 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
NZ538399A (en) * 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
JP2003504074A (ja) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent

Also Published As

Publication number Publication date
US7501125B2 (en) 2009-03-10
AU2006201114B2 (en) 2008-10-23
AU2006201114A1 (en) 2006-04-13
JP2003519668A (ja) 2003-06-24
EP1253939B1 (en) 2009-08-05
ATE438408T1 (de) 2009-08-15
WO2001051081A1 (en) 2001-07-19
US6875435B2 (en) 2005-04-05
US20020146426A1 (en) 2002-10-10
AU1814101A (en) 2001-07-24
EP1253939A1 (en) 2002-11-06
US20050048079A1 (en) 2005-03-03
US20100040645A1 (en) 2010-02-18
CA2396384A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
DE60042704D1 (de) Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
PT724456E (pt) Anticorpos contra cd4
EP1071460A4 (en) INTERNALIZING ERB2 ANTIBODIES
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
WO2001093913A3 (en) T cell receptor fusions and conjugates and methods of use thereof
NO932672L (no) Monokloane antistoffer mot elam-1 og anvendelser derav
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
WO2004020405A3 (en) Modified transferrin fusion proteins
LU93067I2 (fr) Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto)
WO2006020208A3 (en) Therapeutic composition whit a botulinum neurotoxin
WO2003007889A3 (en) Therapeutic agents comprising pro-apoptotic proteins
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EP1537146A4 (en) SELECTED ANTIBODIES AND DURAMYCIN PEPTIDES BINDNING TO ANIONIC PHOSPHOLIPIDES AND AMINOPHOSPHOLIPIDES AND THEIR USE IN THE TREATMENT OF VIRUS INFECTIONS AND CANCER
NO924088L (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera v
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
CY1110661T1 (el) Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
DE50312184D1 (de) Streptavidin-bindungspeptid
AU7525398A (en) Inhibitors for urokinase receptor
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
ATE444081T1 (de) Proteine-abgabe durch polare epithelzellen schichte
WO2002031512A3 (en) Molecular interactions in hematopoietic cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition